July 7, 2025 03:34 PM EDTUpdated 04:26 PM

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

Max Bayer

Pharma Reporter

A group of organizations representing thousands of doctors nationwide sued HHS Secretary Robert F. Kennedy Jr. over his decision to change Covid-19 vaccine recommendations for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

The Supreme Court passed on a state PBM case. Lawyers say a broader legal fight is brewing

KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Trump's tax cut law ex­pands or­phan drug ex­clu­sions, could up­end 340B pro­gram

FDA chief calls for 'mean­ing­ful' re­duc­tion of an­i­mal test­ing for new drugs

De­spite de­lay, KalVista wins FDA ap­proval af­ter Makary's short-lived at­tempt to in­ter­vene

The Supreme Court passed on a state PBM case. Lawyers say a broad­er le­gal fight is brew­ing

KalVista CEO says FDA re­view pro­ceed­ed nor­mal­ly, was un­aware of Makary's re­jec­tion ask

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes

Trump's tax cut law expands orphan drug exclusions, could upend 340B program

FDA chief calls for 'meaningful' reduction of animal testing for new drugs

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene

The Supreme Court passed on a state PBM case. Lawyers say a broader legal fight is brewing

KalVista CEO says FDA review proceeded normally, was unaware of Makary's rejection ask

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases